Number of samples in faecal immunochemical test screening: more might be less
Menée aux Pays-Bas auprès de deux cohortes incluant respectivement 7 310 et 2 269 participants âgés de 50 à 74 ans, cette étude évalue, du point de vue notamment du taux de détection de néoplasies de stade avancé, l'efficacité de quatre sessions d'un programme de dépistage bisannuel comportant un test FIT, en fonction du nombre d'échantillons de selles analysés à chaque session (1 ou 2)
Worldwide, colorectal cancer is the third most common cancer, the second leading cause of cancer death, and its global burden is expected to increase by 60% by 2030. 1
Supported by ample evidence of the benefits of colorectal cancer screening, 2
organised population-based screening programmes are now in place or being implemented in many parts of the world. Among the many decisions that have to be made to optimise the effectiveness of screening programmes, the choice of screening test and its laboratory parameters are the most crucial, and yet the most challenging. Programmes must base their decisions on the available evidence and on the compromises between operational demands, patient acceptance, capacity constraints, and overall programme costs.
The Lancet Gastroenterology & Hepatology , commentaire, 2018